Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.510.35%
QQQ
718.120.12%
BTC/USD
78502.000.7438%
DIA
529.760.81%
GLD
403.050.91%
TLT
81.910.36%

AgomAb Therapeutics NV

AGMBNASDAQ
Trade with Public
Trade with Public
$15.78
0.956.41%
At close: Sep 3, 5:00 PM EST
$13.36
-1.47-9.91%
Pre-Market: 4:24 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentCompareStock Report

AgomAb Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for AgomAb Therapeutics (AGMB).

Price Target Range — 3 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingOverweight# Analysts7Avg. Consensus PT$38Upside to Avg. PT+180.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026Piper SandlerYasmeen RahimiInitiateOverweight$60
Aug 19, 2026Cantor FitzgeraldYanni SouroutzidisInitiateOverweight—
More with Benzinga EdgeGet Access

Analyst Ratings News

This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Avi Kapoor

PRO
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.
Benzinga Newsdesk

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

PRO
Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.
Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On AgomAb Therapeutics with Buy Rating, Announces Price Target of $34

B. Riley Securities analyst William Woods initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Buy rating and announces Price Target of $34.
Benzinga Newsdesk

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Evercore ISI
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved